BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28266080)

  • 1. Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.
    Zhang T; Zhang S; Yang F; Wang L; Zhu S; Qiu B; Li S; Deng Z
    J Cell Biochem; 2018 Jan; 119(1):250-259. PubMed ID: 28266080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials.
    Wang X; Zheng H; Shou T; Tang C; Miao K; Wang P
    J Orthop Surg Res; 2017 Mar; 12(1):52. PubMed ID: 28356114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.
    Albergo JI; Gaston CL; Laitinen M; Darbyshire A; Jeys LM; Sumathi V; Parry M; Peake D; Carter SR; Tillman R; Abudu AT; Grimer RJ
    Bone Joint J; 2016 Aug; 98-B(8):1138-44. PubMed ID: 27482030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
    Fan XL; Cai GP; Zhu LL; Ding GM
    Drug Des Devel Ther; 2015; 9():5925-32. PubMed ID: 26604690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Craft A; Cotterill S; Malcolm A; Spooner D; Grimer R; Souhami R; Imeson J; Lewis I
    J Clin Oncol; 1998 Nov; 16(11):3628-33. PubMed ID: 9817284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
    Tanaka K; Matsunobu T; Sakamoto A; Matsuda S; Iwamoto Y
    J Orthop Sci; 2002; 7(4):477-82. PubMed ID: 12181663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease.
    Ahmed SK; Robinson SI; Okuno SH; Rose PS; Issa Laack NN
    Am J Clin Oncol; 2014 Oct; 37(5):423-9. PubMed ID: 23388557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
    J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
    J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
    Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse after high-dose therapy in relapsed Ewing's tumor patients: effects of maintenance chemotherapy in two selected patients?
    Laws HJ; van Kaick B; Pape H; Paulussen M; Göbel U
    Onkologie; 2003 Dec; 26(6):573-7. PubMed ID: 14709933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
    Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
    Ataergin S; Ozet A; Solchaga L; Turan M; Beyzadeoglu M; Oysul K; Arpaci F; Komurcu S; Surenkok S; Ozturk M
    Med Oncol; 2009; 26(3):276-86. PubMed ID: 18989798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.